Avalyn Pharma Inc.
BioSniper AI · AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for serious rare respiratory diseases, with its lead product AP01 (inhaled pirfenidone) in Phase 2b for progressive pulmonary fibrosis and a recent IPO raising gross proceeds from an upsized offering.
Key risk: Clinical-stage, no approved products
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 5 of 6 signals
Tracking 2 pipeline candidates · 1 catalyst for Avalyn Pharma Inc. · Updated within the last hour.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for serious rare respiratory diseases, with its lead product AP01 (inhaled pirfenidone) in Phase 2b for progressive pulmonary fibrosis and a recent IPO raising gross proceeds from an upsized offering.
- Completed an upsized initial public offering (IPO) of 19,166,667 shares at $18.00 per share, including full exercise of the underwriters' overallotment option, closing on May 1, 2026 [news].
- Completed target enrollment of 375 patients in the Phase 2b MIST trial of AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis; topline 12-month results expected in the second half of 2027 [news].
- Long-term tolerability data from the ATLAS open-label extension trial of AP01 in pulmonary fibrosis will be presented at EULAR 2026 (June 3-6, 2026) [news].
- Appointed Adam Golden and Frank Salisbury to leadership positions in April 2026 to support long-term growth [news].
- Presented patient-centered research on AP01 delivery and supportive care experiences at the American Thoracic Society 2026 International Conference (May 15-20, 2026) [news].
What works
- Lead product AP01 is an inhaled formulation of pirfenidone, a proven antifibrotic, designed to improve tolerability and lung delivery, potentially addressing a significant unmet need in progressive pulmonary fibrosis [news].
- The company has completed enrollment in a 375-patient Phase 2b trial (MIST), suggesting sufficient patient interest and operational execution in a rare disease setting [news].
- Long-term safety and tolerability data from the ATLAS open-label extension trial are being presented at a major medical conference (EULAR 2026), indicating ongoing data generation [news].
- A strong leadership team with recent appointments of industry veterans (Adam Golden, Frank Salisbury, Jon Congleton) supports preparation for potential commercialization [news].
What to weigh
- Avalyn is a clinical-stage company with no approved products or revenue, and its future depends on the successful development and regulatory approval of AP01 [news].
- The Phase 2b MIST trial results are not expected until the second half of 2027, meaning several years of development and investment remain before potential market entry [news].
- The company's lead asset AP01 is an inhaled reformulation of an existing drug (pirfenidone), which may face patent or competitive challenges from generic or other inhaled therapies [news].
- As a newly public company, Avalyn may face investor scrutiny with limited financial history and reliance on future capital raises to fund operations [news].
From the filings
Quoted directly from source documents.
Long-term tolerability data from ATLAS open-label extension trial will be presented at EULAR 2026.
“Updated findings from the ATLAS open-label extension trial will highlight the long-term tolerability profile o”
News · May 21, 2026
Risks & what to watch (4)›
Key risks
- Clinical-stage, no approved products — Avalyn has no marketed products and relies entirely on the success of its clinical programs, particularly AP01, which is still in Phase 2 [news].
- Long timeline to Phase 2b results
- Dependence on inhaled pirfenidone reformulation — AP01 is an inhaled version of an existing drug; efficacy/safety differentiation from oral pirfenidone must be proven, and patent protection may be challenged [news].
- Competitive and market risk — Multiple other inhaled antifibrotic therapies are in development, and oral pirfenidone is already approved, potentially limiting market uptake [news].
What to watch
- Presentation of long-term tolerability data from ATLAS open-label extension trial at EULAR 2026 (June 3-6, 2026) [news].
- Company overview presentation at Jefferies Global Healthcare Conference on June 4, 2026 [news].
- Topline 12-month clinical results from Phase 2b MIST trial expected in the second half of 2027 [news].
- Any additional data from the ATLAS trial or other clinical activities that may be disclosed at future medical conferences [news].
Sources: News · PubMed · Generated July 14, 2026 · How we verify sources →
Unlock the full Avalyn Pharma Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Avalyn Pharma Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
12.4 months
OCF -$30M · Net income -$27M
No tracked pipeline phase
2 candidates
1 upcoming, next in ~534d
4 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Avalyn Pharma Inc.?
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for serious rare respiratory diseases, with its lead product AP01 (inhaled pirfenidone) in Phase 2b for progressive pulmonary fibrosis and a recent IPO raising gross proceeds from an upsized offering.
What is Avalyn Pharma Inc.'s next catalyst?
Avalyn Pharma Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ap01" — expected December 31, 2027.
Who is the CEO of Avalyn Pharma Inc.?
Ms. Lyn Baranowski is the chief executive officer of Avalyn Pharma Inc. (AVLN).
Where is Avalyn Pharma Inc. headquartered?
Avalyn Pharma Inc. (AVLN) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Avalyn Pharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.